Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and insights

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Catch up on the latest press releases and download media assets here

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Innovative Medicine
      August 21, 2015

      Janssen Submits European Extension Marketing Authorisation Application for Paliperidone Palmitate Once-Every-Three-Months Formulation

      First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults
      Learn more
      Innovative Medicine
      July 24, 2015

      Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir

      Filing Supported by Data from the Phase 3 OPTIMIST-1 and -2 Clinical Trials Evaluating OLYSIO® Combination Therapy in Hepatitis C Patients with and without Cirrhosis
      Learn more
      Innovative Medicine
      June 1, 2015

      Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

      Oral presentation (abstract 10503) featured at the Annual Meeting of the American Society of Clinical Oncology
      Learn more
      Innovative Medicine
      May 28, 2015

      New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

      Janssen Expands EXPLORER Cardiovascular Research Program to Include New, Multi-Trial, Prospective Research Program Aimed at Generating New Evidence in Treating and Preventing Cancer-Associated Blood Clots
      Learn more
      Innovative Medicine
      May 22, 2015

      Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia

      A rare B-cell lymphoma with no EMA-approved treatment options available
      Learn more
      Innovative Medicine
      May 19, 2015

      U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia

      93% of patients treated with INVEGA TRINZA™ remained relapse-free at the end of long-term maintenance trial
      Learn more
      Innovative Medicine
      April 15, 2015

      Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

      Learn more
      Innovative Medicine
      April 8, 2015

      Janssen Highlights Hepatitis C Virus Development Program at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

      Presentations include late-breaking final results from the Phase 3 OPTIMIST trials and interim results from the Phase 2 IMPACT trial of simeprevir
      Learn more
      Innovative Medicine
      February 11, 2015

      Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF

      Unique Approach Aims to Intercept Disease Prior to Onset and Preserve Health of People At-risk of Developing Type 1 Diabetes
      Learn more
      Load More